Citations

Clear

350 citation(s) found for "Stevens, V".

Disseminated intravascular coagulopathy: a complication of Stevens–Johnson syndrome/toxic epidermal necrolysis
el‐Azhary, Rokea A. , Nowsheen, Somaira , Gibson, Lawrence E. , DiCaudo, David J. , El-Azhary, Rokea

Mayo Clinic

International Journal of Dermatology | December 18, 2020 | Volume: 60 | Issue: 2 | Pages: 185-189

10.1111/ijd.15370 | PMID 33332598 Get It

AbstractBackgroundThe purpose of this study was to retrospectively assess clinical characteristics and mortality rate of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients who developed disseminated intravascular coagulation (DIC).MethodsA systematic retrospective chart review of all patients with concurrent clinical diagnosis of DIC and SJS/TEN between July 1, 2012, and January 1, 2020, at the Mayo Clinic was performed.ResultsThe incidence of DIC in patients with SJS/TEN was 1.3% at our institution (5 of 396 DIC patients). Triggers of SJS/TEN included lamotrigine, clofarabine, antibiotics, and sepsis. Two patients diagnosed with SJS and two patients with TEN succumbed to the disease.ConclusionDIC is a rare underlying risk in patients with SJS/TEN and is associated with increased mortality. Early clinician awareness and aggressive intervention is advised.
CERTL reduces C16 ceramide, amyloid-β levels and inflammation in a model of Alzheimer's disease
Luo, Qian , Stevens, Jo , Giovagnoni, Caterina, Bode, Gerard H., Hobo, Barbara , Scheithauer, Anna-Lena, Hove, Daniël L.A. van den, Verhaagen, Joost , Bieberich, Erhard , Crivelli, Simone Mwenda , Kruining, Daan van , Hoedt, Sandra den , Walter, Jochen , Mulder, Monique T , Exley, Christopher , Mold, Matthew John , Mielke, Michelle M. , Vries, Helga E. de , Wouters, Kristiaan , Berkeš, Dušan , Ledesma, María Dolores , Losen, Mario , Martínez‐Martínez, Pilar

Mayo Clinic

No container title available | December 9, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-42740/v2 Get It

Abstract Background: Dysregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers, crucial for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.Methods: The plasmid expressing CERTL, the long isoform of CERTs, was used to study the interaction of CERTL with amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescence in HEK cells. The recombinant CERTL protein was employed to study interaction of CERTL with amyloid-β (Aβ), Aβ aggregation process in presence of CERTL, and the resulting changes in Aβ toxicity in neuroblastoma cells. CERTL was overexpressed in neurons by adeno associated virus (AAV) in a familial mouse model of familial AD (5xFAD). Ten weeks after transduction, animals were challenged with behavior tests for memory, anxiety and locomotion. At week twelve, brains were investigated for sphingolipid levels by mass spectrometry, plaques and neuroinflammation by immunohistochemistry, gene expression and/or immunoassay.Results: Here, we report that CERTL, binds to APP, modifies Aβ aggregation and reduces Aβ neurotoxicity in vitro. Furthermore, we show that intracortical injection of AAV, mediating the expression of CERTL, decreases levels of ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male 5xFAD mice. CERTL in vivo over-expression has a mild effect on animal locomotion, decreases Aβ formation and modulates microglia by decreasing their pro-inflammatory phenotype.Conclusion: Our results demonstrate a crucial role of CERTL in regulating ceramide levels in the brain, in amyloid plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and other neurodegenerative diseases.
Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients
Bryant, Laura , Li, Dong , Cox, Samuel G., Wilson, Khadija , Janssen, Kevin A. , March, Michael , Sherr, Elliott H. , Fregeau, Brieana, Wierenga, Klaas J. , Wadley, Alexandrea, Mancini, Grazia M.S., Powell‐Hamilton, Nina , Kamp, Jiddeke van de, Grebe, Theresa A., Ross, Alison , Crawford, Heather P., Powis, Zöe , Cho, Megan T. , Willing, Marcia, Schot, Rachel , Afenjar, Alexandra , Lessel, Davor , Wagner, Matias , Klopstock, Thomas , Winkelmann, Juliane , Retterer, Kyle , Schuette, Jane L., Innis, Jeffrey W. , Pizzino, Amy , Lüttgen, Sabine, Denecke, Jonas , Strom, Tim M., Monaghan, Kristin G. , Study, DDD, Yuan, Zuo‐Fei , Dubbs, Holly , Bend, Renee, Lee, Jennifer A. , Lyons, Michael J. , Hoefele, Julia , Günthner, Roman , Keren, Boris , Radtke, Kelly, Sherbini, Omar , Mrokse, Cameron, Helbig, Katherine L. , Odent, Sylvie , Mercier, Sandra , Küry, Sébastien , Redon, Richard , Reinson, Karit , Wojcik, Monica H. , Õunap, Katrin , Ilves, Pilvi , Innes, A. Micheil , Kernohan, Kristin D. , Costain, Gregory , Zackai, Elaine H. , Kitson, Hilary, Study, CAUSES, Martin, Martin G., Martínez-Agosto, Julián A. , Network, Undiagnosed Diseases, Nelson, Stan F., Palmer, Christina G.S. , Papp, Jeanette C. , Parker, Neil H., Wan, Jijun , Yoon, Amanda J., Zheng, Allison, Carli, Diana , Brusco, Alfredo , Tartaglia, Marco , Thomas, Jennifer Muncy, Weiss, Marjan M. , Gotway, Garrett , Stuurman, Kyra E. , Thompson, Michelle L. , Stumpel, Constance T. R. M., Stevens, Servi J.C. , Stegmann, Alexander P.A. , Tveten, Kristian , Vøllo, Arve, Prescott, Trine , Fagerberg, Christina , Laulund, Lone Walentin , Larsen, Martin J. , Byler, Melissa, Lebel, Robert Roger, Dean, Joy, Mercimek‐Andrews, Saadet , Neira, Juanita, Allen, Margot I. Van, Sellars, Elizabeth A. , Louie, Raymond J. , Cathey, Sara , Brokamp, Elly , Héron, Delphine, Snyder, Molly, Simon, Celeste, Cruz, Xavier de la , Padilla, Natàlia , García, Benjamin A. , Håkonarson, Håkon , Bhoj, Elizabeth , Nelson, Stanley F. , Sherr, Elliott , Dean, John , Lessel, Davor , Klopstock, Thomas , Kury, Sebastien , Brusco, Alfredo , McWalter, Kirsty , Stevens, Servi J C , Crump, J Gage , Hakonarson, Hakon , Bhoj, Elizabeth J , Tartaglia, Marco , Li, Dong , Wagner, Matias , Redon, Richard , Õunap, Katrin , de la Cruz, Xavier , Padilla, Natália , March, Michael , Hoefele, Julia , Marchione, Dylan M. , Joiner, Evan F. , Lee, Pearl , Nair, Divya, Kamp, Jiddeke M. van de , Manwaring, Linda P. , Nava, Caroline , Catarino, Claudia B. , Monaghan, Kristin G. , Study, DDD, Reutter, Heiko , Radtke, Kelly , Cogné, Benjamin , Bezieau, Stéphane , Besnard, Thomas , Meyn, M Stephen , Chitayat, David A. , Lehman, Anna , Study, CAUSES, Network, Undiagnosed Diseases, Sinsheimer, Janet S. , Vilain, Eric J. N. , Brimble, Elise , Ferrero, Giovanni Battista , Radio, Francesca Clementina , Barresi, Sabina , Umaña, Luis Alfredo , Hurst, Anna , Vergano, Samantha A. Schrier , Norman, Jennifer, Longo, Nicola , Vanderver, Adeline , Chung, Wendy K.

Mayo Clinic

Science Advances | December 3, 2020 | Volume: 6 | Issue: 49 | Pages: No page available

10.1126/sciadv.abc9207 | PMID 33268356 Get It

Germ line mutations in H3F3A and H3F3B cause a previously unidentified neurodevelopmental syndrome.
Differences between Stevens‐Johnson syndrome versus toxic epidermal necrolysis
Nowsheen, Somaira , Lehman, Julia S. , El-Azhary, Rokea A, Lehman, Julia S , el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | November 30, 2020 | Volume: 60 | Issue: 1 | Pages: 53-59

10.1111/ijd.15287 | PMID 33252832 Get It

AbstractBackgroundTo retrospectively review the outcomes of two rare cutaneous diseases, Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and to question the practice of averaging the mortality rate on the assumption that they are one disease.MethodsA retrospective chart review of all patients diagnosed with SJS and TEN by a dermatologist between January 1, 2000, and January 1, 2020, at our institution was performed. Seventy‐one patients were identified (21 pediatric and 50 adults). Pathology slides from 32 adult patients (64%) were evaluated by a blinded board‐certified dermatopathologist.ResultsOf the adult patients, 31 had SJS, two had SJS‐TEN overlap, and 17 had TEN. All 21 patients in the pediatric group were diagnosed with SJS mainly caused by Mycoplasma. Mortality rates were 6.5% for SJS among adults and 35.3% for TEN. Chemotherapy‐induced TEN is a trigger with 50% mortality.ConclusionsSJS was more common in adults and pediatric cases than TEN (3:1) and had a much better prognosis and outcome. Combining and averaging the mortality rates of TEN and SJS are not advised as SJS is mainly a mucocutaneous disorder with good prognosis versus TEN, a systemic toxicity of multiple organs with deep skin detachment.
Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery
Gregory, Anne, Stapelfeldt, Wolf H. , Boero, Isabel J., Chen, Qinyu , Stevens, Mitali, Smischney, Nathan J. , Khanna, Ashish K. , Shaw, Andrew

Mayo Clinic

Anesthesia & Analgesia | November 11, 2020 | Volume: 132 | Issue: 6 | Pages: 1654-1665

10.1213/ane.0000000000005250 | PMID 33177322 Get It

BACKGROUND: Intraoperative hypotension (IOH) occurs frequently during surgery and may be associated with organ ischemia; however, few multicenter studies report data regarding its associations with adverse postoperative outcomes across varying hemodynamic thresholds. Additionally, no study has evaluated the association between IOH exposure and adverse outcomes among patients by various age groups. METHODS: A multicenter retrospective cohort study was conducted between 2008 and 2017 using intraoperative blood pressure data from the US electronic health records database to examine postoperative outcomes. IOH was assessed in 368,222 noncardiac surgical procedures using 5 methods: (a) absolute maximum decrease in mean arterial pressure (MAP) during surgery, (b) time under each absolute threshold, (c) total area under each threshold, (d) time-weighted average MAP under each threshold, and (e) cumulative time under the prespecified relative MAP thresholds. MAP thresholds were defined by absolute limits (≤75, ≤65, ≤55 mm Hg) and by relative limits (20% and 40% lower than baseline). The primary outcome was major adverse cardiac or cerebrovascular events; secondary outcomes were all-cause 30- and 90-day mortality, 30-day acute myocardial injury, and 30-day acute ischemic stroke. Residual confounding was minimized by controlling for observable patient and surgical factors. In addition, we stratified patients into age subgroups (18–40, 41–50, 51–60, 61–70, 71–80, >80) to investigate how the association between hypotension and the likelihood of major adverse cardiac or cerebrovascular events and acute kidney injury differs in these age subgroups. RESULTS: IOH was common with at least 1 reading of MAP ≤75 mm Hg occurring in 39.5% (145,743) of cases; ≤65 mm Hg in 19.3% (70,938) of cases, and ≤55 mm Hg in 7.5% (27,473) of cases. IOH was significantly associated with the primary outcome for all age groups. For an absolute maximum decrease, the estimated odds of a major adverse cardiac or cerebrovascular events in the 30-day postsurgery was increased by 12% (95% confidence interval [CI], 11-14) for ≤75 mm Hg; 17.0% (95% CI, 15-19) for ≤65 mm Hg; and by 26.0% (95% CI, 22-29) for ≤55 mm Hg. CONCLUSIONS: IOH during noncardiac surgery is common and associated with increased 30-day major adverse cardiac or cerebrovascular events. This observation is magnified with increasing hypotension severity. The potentially avoidable nature of the hazard, and the extent of the exposed population, makes hypotension in the operating room a serious public health issue that should not be ignored for any age group.
Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group
Parzen, Jacob S. , Hartsell, William F. , Chang, John P., Molitoris, Jason K. , Durci, Michael, Urbanic, James J., Ashman, Jonathan B. , Vargas, Carlos , Stevens, Craig, Kabolizadeh, Peyman, Apisarnthanarax, Smith , Tsai, Henry K.

Mayo Clinic

No container title available | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-70862/v2 Get It

Abstract Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume while sparing the uninvolved liver. This study evaluated the safety and efficacy of hypofractionated PBT for liver tumors, predominantly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).Methods: We evaluated the prospective registry of the Proton Collaborative Group for patients undergoing definitive PBT for liver tumors. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled.Results: To date, 63 patients have been treated at 9 institutions between 2013-2019. Thirty (48%) had HCC and 25 (40%) had ICC. The median dose and biological equivalent dose (BED) delivered was 58.05 GyE (range, 32.5-75) and 80.5 GyE (range, 53.6-100), respectively. The median mean liver BED was 13.9 GyE. Three (4.8%) patients experienced at least one grade ³3 toxicity. With median follow-up of 5.1 months (range, 0.1-40.8), the local control (LC) rate at 1 year was 91.2% for HCC and 90.9% for ICC. The 1-year LC was significantly higher (95.7%) for patients receiving BED greater than 75.2 GyE than for patients receiving BED of 75.2 GyE or lower (84.6%, p = 0.029). The overall survival rate at 1 year was 65.6% for HCC and 81.8% for ICC. Conclusions: Hypofractionated PBT results in excellent LC, sparing of the uninvolved liver, and low toxicity, even in the setting of dose-escalation. Higher dose correlates with improved LC, highlighting the importance of PBT especially in patients with recurrent or bulky disease.
Prediction of Vancomycin Levels Using Cystatin C in Overweight and Obese Patients: a Retrospective Cohort Study of Hospitalized Patients
Teaford, Hilary R. , Mara, Kristin C. , Frazee, Erin N. , O'horo, John, Frazee, Erin N , Mara, Kristin C , Stevens, Ryan W. , Rule, Andrew D. , Kashani, Kianoush , Lieske, John C. , O’Horo, John C.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 22, 2020 | Volume: 65 | Issue: 1 | Pages: No page available

10.1128/aac.01487-20 | PMID 33106257 Get It

The use of the kidney function biomarker cystatin C (cysC) can improve the accuracy of vancomycin dosing for target trough attainment in nonobese patients. It is unknown whether cysC can also improve vancomycin target trough attainment in overweight and obese patients. We conducted a retrospective observational study of overweight or obese hospitalized adults with stable renal function administered intravenous vancomycin between January 2011 and July 2019. Linear regression models were used to predict initial steady-state vancomycin troughs using several factors, including various cysC- and serum creatinine (SCr)-based estimates of kidney function.
Effectiveness of Contact Precautions to Prevent Transmission of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci in Intensive Care Units
Khader, Karim , Keegan, Lindsay T. , Samore, Matthew H. , Thomas, Alun , Huskins, W. Charles , Stevens, Vanessa W , Visnovsky, Lindsay D.

Mayo Clinic

Clinical Infectious Diseases | October 16, 2020 | Volume: 72 | Issue: Supplement_1 | Pages: S42-S49

10.1093/cid/ciaa1603 | PMID 33512528 Get It

Abstract Background Contact precautions for endemic methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are under increasing scrutiny, in part due to limited clinical trial evidence. Methods We retrospectively analyzed data from the Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR*ICU) trial to model the use of contact precautions in individual intensive care units (ICUs). Data included admission and discharge times and surveillance test results. We used a transmission model to estimate key epidemiological parameters, including the effect of contact precautions on transmission. Finally, we performed multivariate meta-regression to identify ICU-level factors associated with contact precaution effects. Results We found that 21% of admissions (n = 2194) were placed on contact precautions, with most for MRSA and VRE. We found little evidence that contact precautions reduced MRSA transmission. The estimated change in transmission attributed to contact precautions was –16% (95% credible interval, –38% to 15%). VRE transmission was higher than MRSA transmission due to contact precautions, but not significantly. In our meta-regression, we did not identify associations between ICU-level factors and estimated contact precaution effects. Importation and transmission were higher for VRE than for MRSA, but clearance rates were lower for VRE than for MRSA. Conclusions We found little evidence that contact precautions implemented during the STAR*ICU trial reduced transmission of MRSA or VRE. We did find important differences in the transmission dynamics between MRSA and VRE. Differences in organism and healthcare setting may impact the efficacy of contact precautions.
Cystatin C regulates the cytotoxicity of infection‐induced endothelial‐derived β‐amyloid
Balczon, Ron , Morrow, K. Adam, Leavesley, Silas J. , Francis, C. Michael , Stevens, Trevor C., Agwaramgbo, Ezinne, Stevens, R.P. , Langham, Geri, Voth, S.B. , Cioffi, Eugene A., Weintraub, Susan, Stevens, Troy , Leavesley, Silas , Williams, Christopher, Weintraub, Susan T.

Mayo Clinic

FEBS Open Bio | October 8, 2020 | Volume: 10 | Issue: 11 | Pages: 2464-2477

10.1002/2211-5463.12997 | PMID 33030263 Get It

Infection of rat pulmonary microvascular endothelial cells with the bacterium Pseudomonas aeruginosa induces the production and release of cytotoxic oligomeric tau and beta amyloid (Aβ). Here, we characterized these cytotoxic amyloids. Cytotoxic behavior and oligomeric tau were partially resistant to digestion with proteinase K, but cytotoxicity was abolished by various denaturants including phenol, diethylpyrocarbonate (DEPC), and 1,1,1,3,3,3‐hexafluoro‐2‐isopropanol (HFIP). Ultracentrifugation for 8 h at 150 000 g was required to remove cytotoxic activity from the supernatant. Ultracentrifugation, DEPC treatment, and immunodepletion using antibodies against Aβ also demonstrated that cytoprotective protein(s) are released from endothelial cells during P. aeruginosa infection. Mass spectrometry of endothelial cell culture media following P. aeruginosa infection allowed identification of multiple potential secreted modulators of Aβ, including cystatin C, gelsolin, and ApoJ/clusterin. Immunodepletion, co‐immunoprecipitation, and ultracentrifugation determined that the cytoprotective factor released during infection of endothelial cells by P. aeruginosa is cystatin C, which appears to be in a complex with Aβ. Cytoprotective cystatin C may provide a novel therapeutic avenue for protection against the long‐term consequences of infection with P. aeruginosa.
Intelligence, educational attainment, and brain structure in those at familial high‐risk for schizophrenia or bipolar disorder
Zwarte, Sonja M. C. de , Brouwer, Rachel M. , Agartz, Ingrid , Alda, Martin , Alonso-Lana, Sílvia , Bearden, Carrie E. , Bonvino, Aurora , Bramon, Elvira , Buimer, Elizabeth E.L. , Canales‐Rodríguez, Erick J. , Cannon, Dara M. , Cannon, Tyrone D. , Caseras, Xavier , Chen, Qiang , Chung, Yoonho , Serna, Elena de la , Giorgio, Annabella Di , Eker, Çağdaş , Erk, Susanne , Fatjó‐Vilas, Mar , Fears, Scott C. , Foley, Sonya , Fullerton, Janice M. , Goghari, Vina M. , Goikolea, José Manuel , Goldman, Aaron L. , Gruber, Oliver , Hájek, Tomáš , Hawkins, Emma L. , Heinz, Andreas , Hıdıroğlu, Ceren , Hillegers, Manon H. J. , Houenou, Josselin , Pol, Hilleke E. Hulshoff , Hultman, Christina M., Johansson, Viktoria , Jönsson, Erik G. , Kane, Fergus , Kempton, Matthew J. , Kopeček, Miloslav , Krämer, Bernd , Lenroot, Rhoshel , Marcelis, Machteld , Mattay, Venkata S. , Meyer‐Lindenberg, Andreas , Mwangi, Benson , Nabulsi, Leila , Newport, Jason, Olman, Cheryl A. , Overs, Bronwyn J. , Özerdem, Ayşegül , Pergola, Giulio , Pomarol‐Clotet, Edith , Raduà, Joaquim , Ramsay, Ian S. , Roberts, Gloria , Salvador, Raymond , Sarıçiçek, Aybala , Sarró, Salvador , Simsek, Esma M., Şimşek, Fatma , Toulopoulou, Timothea , Vieta, Eduard , Walter, Henrik , Weinberger, Daniel R. , Whalley, Heather C. , Yalın, Nefize , Ching, Christopher R. K. , Thomopoulos, Sophia I. , Jahanshad, Neda , Thompson, Paul M. , Kahn, René S. , Haren, Neeltje E.M. van , de Zwarte, Sonja M C , Bramon, Elvira , Canales-Rodríguez, Erick J , Cannon, Tyrone D , Chung, Yoonho , Di Giorgio, Annabella , Doucet, Gaelle E , Eker, Mehmet Cagdas , Frangou, Sophia , Glahn, David C , Hajek, Tomas , Hulshoff Pol, Hilleke E , Johansson, Viktoria , Jönsson, Erik G , Koenis, Marinka M G , Kopecek, Miloslav , Krämer, Bernd , Michielse, Stijn , Pergola, Giulio , Pomarol-Clotet, Edith , Radua, Joaquim , Salvador, Raymond , Saricicek Aydogan, Aybala , Sarró, Salvador , Schofield, Peter R , Simsek, Fatma , Sponheim, Scott R , Sugranyes, Gisela , Vieta, E , Ching, Christopher R K , Thomopoulos, Sophia I , van Erp, Theo G M , Agartz, Ingrid , Buimer, Elizabeth E L , van Haren, Neeltje E M , Hillegers, Manon H J , Meyer-Lindenberg, Andreas , Walter, Henrik , Thompson, Paul M , Alda, Martin , Fullerton, Janice M , Ozerdem, Aysegul , Yalin, Nefize , Bertolino, Alessandro , Cahn, Wiepke , Castro‐Fornieles, Josefina , Bonnín, Caterina del Mar , Demro, Caroline , Frangou, Sophia , Gönül, Ali Saffet , Ingvar, Martin , Lawrie, Stephen M. , McDonald, Colm , Mitchell, Philip B , Moreno, Dolores Maria , Murray, Robin , Os, Jim van , Picchioni, Marco , Piguet, Camille , Richter, Anja , Schofield, Peter R. , Soares, Jair C. , Tronchin, Giulia , Wu, Mon‐Ju , Andreassen, Ole A.

Mayo Clinic

Human Brain Mapping | October 7, 2020 | Volume: 43 | Issue: 1 | Pages: 414-430

10.1002/hbm.25206 | PMID 33027543 Get It

AbstractFirst‐degree relatives of patients diagnosed with schizophrenia (SZ‐FDRs) show similar patterns of brain abnormalities and cognitive alterations to patients, albeit with smaller effect sizes. First‐degree relatives of patients diagnosed with bipolar disorder (BD‐FDRs) show divergent patterns; on average, intracranial volume is larger compared to controls, and findings on cognitive alterations in BD‐FDRs are inconsistent. Here, we performed a meta‐analysis of global and regional brain measures (cortical and subcortical), current IQ, and educational attainment in 5,795 individuals (1,103 SZ‐FDRs, 867 BD‐FDRs, 2,190 controls, 942 schizophrenia patients, 693 bipolar patients) from 36 schizophrenia and/or bipolar disorder family cohorts, with standardized methods. Compared to controls, SZ‐FDRs showed a pattern of widespread thinner cortex, while BD‐FDRs had widespread larger cortical surface area. IQ was lower in SZ‐FDRs (d = −0.42,p = 3 × 10−5), with weak evidence of IQ reductions among BD‐FDRs (d = −0.23,p = .045). Both relative groups had similar educational attainment compared to controls. When adjusting for IQ or educational attainment, the group‐effects on brain measures changed, albeit modestly. Changes were in the expected direction, with less pronounced brain abnormalities in SZ‐FDRs and more pronounced effects in BD‐FDRs. To conclude, SZ‐FDRs and BD‐FDRs show a differential pattern of structural brain abnormalities. In contrast, both had lower IQ scores and similar school achievements compared to controls. Given that brain differences between SZ‐FDRs and BD‐FDRs remain after adjusting for IQ or educational attainment, we suggest that differential brain developmental processes underlying predisposition for schizophrenia or bipolar disorder are likely independent of general cognitive impairment.